AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== United Kingdom === In 1902, Force wheat flakes became the first ready-to-eat breakfast cereal introduced into the United Kingdom. The cereal, and the Sunny Jim character, achieved wide success in Britain, at its peak in 1930 selling 12.5 million packages in one year.
== History == The glucose clamp technique was developed by University of Texas (UT) School of Medicine Professors DeFronzo, Andres and Tobin in 1979. It has since been the gold standard for pharmacodynamic studies in diabetes drug development and diagnostics evaluation. In human clinical trials, manual glucose clamps as well as the more modern method of automated glucose clamp find common use.
In January 2024, Galloway announced that he would stand in the Rochdale by-election the following month, again for the Workers Party of Britain. Galloway claimed he received a text from Richard Tice to be the Reform UK party candidate. He was elected in a political upset after Azhar Ali, the Labour candidate, lost the support of his party due to comments made regarding the Hamas-led attack on Israel. Galloway won almost 40% of the vote and overturned a Labour majority of 9,668. The Gaza war dominated the campaign. In his election speech, Galloway said "Keir Starmer, this is for Gaza. You will pay a high price for the role that you have played in enabling, encouraging and covering for the catastrophe presently going on in occupied Gaza, in the Gaza Strip". Alluding to the size of his win over the Labour and Conservative candidates, he said, "Keir Starmer and Rishi Sunak are two cheeks of the same backside and they both got well and truly spanked tonight here in Rochdale." Galloway chose to make a religious oath rather than a secular affirmation when being sworn into parliament; in which he held a Bible and swore allegiance to King Charles and his heirs upon God. On 23 May 2024, Galloway confirmed he would be running for re-election in Rochdale at the 2024 general election. Galloway polled 11,508 votes and lost the seat to Labour's Paul Waugh, who polled 13,047 votes. Galloway did not attend the vote count. He was MP for Rochdale for 92 days.
== History == The first documented case of gutter oil in Taiwan was reported in 1985. In a subsequent investigation, 22 people were arrested for involvement in a recycling oil ring over 10 years based in Taipei. The worst offender was sentenced to 7 years in prison. The first documented case of gutter oil in mainland China was reported in 2000, when a street vendor was found to be selling oil obtained from restaurant garbage disposals. Some street vendors and restaurants in China are reported to have illegally used recycled oil unfit for human consumption to cook food. In 2010, it was estimated that gutter oil represented 10% of China's edible oil market (with 1 in every 10 restaurants using it) and that 3 million tonnes of gutter oil were consumed in China annually, with a network of distributors of gutter oil across central and eastern China. In 2011, the Chinese government began a major crackdown on the re-use of gutter oil for human consumption. In 2011, they arrested 32 people for producing the oil and seized 90 tonnes of it in 14 provinces. This amount is equivalent to around one-tenth of the oil typically used by restaurants. Feng Ping of the China Meat Research Center has said that "[t]he illegal oil shows no difference in appearance and indicators after refining and purification, because the law breakers are skillful at coping with the established standards." In September 2012, an ongoing investigation into the suspected use of gutter oil as a raw material in the Chinese pharmaceutical industry was revealed.
== Diagnosis == Myasthenia gravis can be difficult to diagnose, as the symptoms can be subtle and hard to distinguish from both normal variants and other neurological disorders. Three types of myasthenic symptoms in children can be distinguished:
Sources: en.wikipedia.org
In 1977, the exiled Republicans accepted the re-establishment of the monarchy and recognised Juan Carlos's government as the legitimate government of Spain. The key moment came when socialist leaders Felipe González and Javier Solana met Juan Carlos at Zarzuela Palace in Madrid — a tacit endorsement of the monarchy by the previously staunchly republican Socialists. On 1 July 1977, the Government of the Spanish Republic was formally dissolved. In a gesture of reconciliation, Juan Carlos received the exiled leaders at a ceremony in Madrid.
== Related compounds == N-Methyliminodiacetic acid (MIDA), the N-methyl derivative of IDA Imidodiacetic acid, the amino diacetic acid N-(2-Carboxyethyl)iminodiacetic acid, a more biodegradable analogue of NTA N-hydroxyiminodiacetic acid (HIDA), HON(CH2CO2H)2 (registry number = 87339-38-6) See HIDA scan.
There were proposals to extend this corridor 7 miles to Chapel Hill with light rail technology. However, in 2006 Triangle Transit deferred implementation indefinitely when the Federal Transit Administration declined to fund the program due to low ridership projections. The region's two metropolitan planning organizations appointed a group of local citizens in 2007 to reexamine options for future transit development in light of Triangle Transit's problems. The Special Transit Advisory Commission (STAC) retained many of the provisions of Triangle Transit's original plan but recommended adding new bus services and raising additional revenues by adding a new local half-cent sales tax to fund the project. Greyhound Lines provides an inter-city bus service to Durham, Charlotte, Richmond, Washington, D.C., Atlanta, and other cities.
Agonists Cortagine Corticorelin Corticotropin-releasing hormone Sauvagine Stressin I Urocortin Antagonists Antalarmin Astressin-B CP-154,526 Emicerfont Hypericin LWH-234 NBI-27914 NBI-74788 Pexacerfont R-121919 TS-041 Verucerfont
Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. It is a first generation retinoid. Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
Sources: en.wikipedia.org
Chain Home radar installations were normally composed of two sites. One compound contained the transmitter towers with associated structures, and a second compound, normally within a few hundred metres distance, contained the receiver masts and receiver equipment block where the operators (principally WAAF, Women's Auxiliary Air Force) worked. The CH system was, by modern terminology, a "bistatic radar", although modern examples normally have their transmitters and receivers far more widely separated. The transmitter antenna consisted of four steel towers 360 feet (110 m) tall, set out in a line about 180 feet (55 m) apart. Three large platforms were stationed on the tower, at 50, 200 and 350 feet off the ground. A 600 ohm transmission cable was suspended from the top platform to the ground on either side of the platform (only on the inside of the end towers). Between these vertical feed cables were the antennas proper, eight half-wave dipoles strung between the vertical cables and spaced ½ of a wavelength apart. They were fed from alternating sides so the entire array of cables was in-phase, given their ½ wavelength spacing. Located behind each dipole was a passive reflector wire, spaced 0.18 wavelength back. The resulting curtain array antenna produced a horizontally polarised signal that was directed strongly forward along the perpendicular to the line of the towers. This direction was known as the line of shoot, and was generally aimed out over the water.
Subsequent lodges were formed in Washington, D.C., and Philadelphia in 1866 and 1867 respectively. By the late 1890s, the Order was said to have members in almost every state of the Union. State divisions were called Grad Lodges, and the national organization was controlled by a Supreme Lodge of the United States that met "one the first hour of every leap year." Lodge rooms were called Smithies, the presiding officer was titled Sun, the second-in-command was the moon, and other officials had names based on the planets and other bodies in the firmament. The order worked nine degrees, six lower, called the Free Smiths, and three higher degrees - Grand Marshal, Grand Master, and Cavalier - which were open to members who had been in the Order longer and were entitled to wear colored sashes and swords. The motto of the order was Truth, Fidelity, and Security. The order also paid sick and death benefits. Correspondence sent to Baltimore in May 1923 by Arthur Preuss went unanswered. Bavarian National Association of North America - Founded 1884, incorporated in New York. In 1923 the Association had c.3,500 members in 56 lodges; membership "not strictly limited to", natives of Bavaria and their descendants. "Supreme Office" at 749 Broadway, Buffalo, New York. Merged with Unity Life and Accident Insurance Association in 1934. GUG Germania - Gegenseite Unterstutzungsgeselshaft Germania, founded in 1888 and incorporated the same year in Wisconsin, in which state they confined their operations.
Reported risk factors include female sex, obesity, elevated calcium-phosphate product, medications such as warfarin, vitamin D derivatives (e.g. calcitriol, calcium-based binders, or systemic steroids), protein C or S deficiency, low blood albumin levels, and diabetes mellitus. Patients who require or have undergone any type of vascular procedures are also at increased risk for poor outcomes.
The three substrates of this enzyme are formaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are formic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is formaldehyde:NAD+ oxidoreductase. Other names in common use include NAD+-linked formaldehyde dehydrogenase, s-nitrosoglutathione reductase (GSNO reductase) and NAD+-dependent formaldehyde dehydrogenase. This enzyme participates in methane metabolism.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.